bromocriptine

(redirected from Cycloset)
Also found in: Dictionary, Medical.
Related to Cycloset: bromocriptine

bromocriptine

[‚brō·mō′krip‚tēn]
(organic chemistry)
C32H40BrN5O5 A polypeptide alkaloid that is a derivative of the ergotoxin group of ergot alkaloids and is a dopamine receptor agonist.
Mentioned in ?
References in periodicals archive ?
According to San Diego-based Santarus, Cycloset is the only type 2 diabetes drug that has been approved since the Food and Drug Administration issued new guidelines in 2008 to limit the cardiovascular risks associated with some diabetes treatments.
Cycloset received FDA approval in 2009 but has never reached the market.
Over six months, 35 percent of Cycloset users reached recommended average blood sugar levels, compared with 10 percent of diabetics given a dummy drug, Cincotta said.
The Cycloset Safety Study included more than 3,000 patients with T2DM who received either bromocriptine QR or placebo, in conjunction with their usual diabetes therapy.
15 November 2010 - US specialty biopharmaceutical company Santarus Inc (NASDAQ: SNTS) announced today the commercial launch of the Type 2 diabetes drug CYCLOSET (bromocriptine mesylate) tablets in the USA.
lt;p>Speciality biopharmaceutical company Santarus Inc (NASDAQ:SNTS) reported on Wednesday the execution of a distribution and licence agreement to acquire the exclusive rights to manufacture and commercialise CYCLOSET (bromocriptine mesylate) tablets in the US for type 2 diabetes.
CYCLOSET improves glycemic control without increasing cardiovascular event risk.
Cycloset is taken by mouth once daily in the morning, and results in a "brief pulse of dopamine agonist activity shortly after its administration," which improves postprandial glucose without increasing plasma insulin concentrations, according to a statement issued by VeroScience.
Patient groups in the evaluable per protocol (EPP) population that added CYCLOSET to their treatment regimen achieved a 0.
In assessing cardiovascular safety in type 2 diabetes subjects, CYCLOSET demonstrated a significant 52% relative risk reduction in cardiovascular events (composite endpoint of myocardial infarction, stroke and cardiovascular death) compared with placebo
8 million for the third quarter of 2012 included royalties on GLUMETZA net sales, the gross margin split on CYCLOSET net sales, royalties on ZEGERID net sales and amortization of upfront payments.
CYCLOSET (bromocriptine mesylate) tablets new prescriptions increased 131% and total prescriptions were up 100% in the second quarter of 2012 compared with the second quarter of 2011.